Intensity Therapeutics, Inc.
INTS
$0.41
$0.0515.05%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.84% | -22.71% | -37.50% | -20.31% | 24.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.45% | -46.64% | -28.44% | -4.45% | 43.32% |
| Operating Income | 23.45% | 46.64% | 28.44% | 4.45% | -43.32% |
| Income Before Tax | 23.97% | 48.96% | 27.29% | -0.28% | -50.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.97% | 48.96% | 27.29% | -0.28% | -50.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.97% | 48.96% | 27.29% | -0.28% | -50.84% |
| EBIT | 23.45% | 46.64% | 28.44% | 4.45% | -43.32% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 75.60% | 62.90% | 34.31% | 4.12% | -49.27% |
| Normalized Basic EPS | 75.60% | 62.93% | 34.27% | 4.10% | -49.16% |
| EPS Diluted | 75.60% | 62.90% | 34.31% | -91.84% | -49.27% |
| Normalized Diluted EPS | 75.60% | 62.93% | 34.27% | 4.10% | -49.16% |
| Average Basic Shares Outstanding | 211.80% | 37.60% | 10.68% | 4.62% | 1.05% |
| Average Diluted Shares Outstanding | 211.80% | 37.60% | 10.68% | 4.62% | 1.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |